IL150109A0 - Method for administering a cytokine to the central nervous system and the lymphatic system - Google Patents

Method for administering a cytokine to the central nervous system and the lymphatic system

Info

Publication number
IL150109A0
IL150109A0 IL15010900A IL15010900A IL150109A0 IL 150109 A0 IL150109 A0 IL 150109A0 IL 15010900 A IL15010900 A IL 15010900A IL 15010900 A IL15010900 A IL 15010900A IL 150109 A0 IL150109 A0 IL 150109A0
Authority
IL
Israel
Prior art keywords
central nervous
nervous system
cytokine
administering
disorders
Prior art date
Application number
IL15010900A
Other languages
English (en)
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of IL150109A0 publication Critical patent/IL150109A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL15010900A 1999-12-09 2000-12-08 Method for administering a cytokine to the central nervous system and the lymphatic system IL150109A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20070899P 1999-12-09 1999-12-09
PCT/US2000/033220 WO2001041782A2 (en) 1999-12-09 2000-12-08 Method for administering a cytokine to the central nervous system and the lymphatic system

Publications (1)

Publication Number Publication Date
IL150109A0 true IL150109A0 (en) 2002-12-01

Family

ID=22742853

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15010900A IL150109A0 (en) 1999-12-09 2000-12-08 Method for administering a cytokine to the central nervous system and the lymphatic system

Country Status (10)

Country Link
US (3) US20010043915A1 (no)
EP (1) EP1237567B1 (no)
JP (1) JP2003516360A (no)
AT (1) ATE300952T1 (no)
AU (1) AU783208B2 (no)
CA (1) CA2393688A1 (no)
DE (1) DE60021760T2 (no)
IL (1) IL150109A0 (no)
NO (1) NO20022731L (no)
WO (1) WO2001041782A2 (no)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024270A1 (en) * 2000-08-23 2006-02-02 The New York Hospital Medical Center Of Queens Compositions and methods for preventing or treating encephalitis with interferon
US6589591B1 (en) * 2001-07-10 2003-07-08 Baylor College Of Medicine Method for treating medical devices using glycerol and an antimicrobial agent
EP1465547A4 (en) * 2001-12-28 2008-04-30 Genzyme Corp BIODEGRADABLE FOAM PACKAGING DEVICE AND ITS USE
SI1471974T1 (sl) 2002-02-06 2007-12-31 Ares Trading Sa Tumorje nekrotizirajoäśi faktor, kombiniran z interferonom, pri demielinizirajoäśih boleznih
EP1487474A4 (en) * 2002-02-25 2006-11-29 Chiron Corp INTRANASAL ADMINISTRATION OF MC4-R AGONISTS
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
EP1599474B1 (en) 2003-03-04 2013-04-24 California Institute Of Technology Heterocyclic oligomeric compounds for DNA recognition
CN1791423A (zh) * 2003-03-19 2006-06-21 阿雷斯贸易股份有限公司 阿尔茨海默病的治疗
FR2864901B1 (fr) 2004-01-09 2007-10-05 Philippe Perovitch Composition pour le traitement au contact des hyposialies, incluant de la pilocarpine et a effets multiples
WO2005071101A1 (en) * 2004-01-23 2005-08-04 University Hospital Of Basel Treatment of hepatitis c infection by increasing stat1 methylation
US20070212306A1 (en) * 2004-06-07 2007-09-13 Quay Steven C Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides
US7776312B2 (en) * 2004-08-13 2010-08-17 Healthpartners Research Foundation Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
US9216161B2 (en) 2004-08-13 2015-12-22 Healthpartners Research Foundation Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US9114069B2 (en) * 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US20060046969A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
US8642564B2 (en) * 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
KR20080019606A (ko) * 2005-05-04 2008-03-04 나우틸루스 바이오텍 변형된 인터페론-감마 폴리펩티드 및 변형된 인터페론-감마폴리펩티드를 사용하는 방법
JP2009506076A (ja) 2005-08-26 2009-02-12 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 三叉神経疼痛のための薬物送達のための治療手順
US20080003202A1 (en) * 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
EP1915986A1 (en) * 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Lipid growth factor formulations
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
CA2687505C (en) 2007-06-08 2013-10-08 Healthpartners Research Foundation Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
US8221358B2 (en) * 2007-11-20 2012-07-17 Warsaw Orthopedic, Inc. Devices and methods for delivering drug depots to a site beneath the skin
US20090258865A1 (en) * 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US20110129499A1 (en) 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
US9198965B2 (en) 2008-06-13 2015-12-01 Wisconsin Alumni Research Foundation Peptide adjuvant for influenza vaccination
WO2009152519A2 (en) 2008-06-13 2009-12-17 Wisconsin Alumni Research Foundation Novel antiviral peptides against influenza virus
US20100106132A1 (en) * 2008-10-29 2010-04-29 Warsaw Orthopedic, Inc. Drug cartridge for delivering a drug depot comprising superior and inferior covers
US9352137B2 (en) * 2008-10-29 2016-05-31 Warsaw Orthopedic, Inc. Drug cartridge for delivering a drug depot comprising a bulking agent and/or cover
US20100106136A1 (en) * 2008-10-29 2010-04-29 Warsaw Orthopedic, Inc. Drug delivery device with sliding cartridge
EP2375895A4 (en) * 2008-12-11 2012-05-30 Merck Sharp & Dohme METHOD OF TREATING ALZHEIMER'S DISEASE AND RELATED STATES
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
CN103200961B (zh) 2009-03-27 2017-10-27 中央研究院 抗病毒免疫的方法和组合物
WO2011011725A2 (en) 2009-07-24 2011-01-27 Schultz-Cherry Stacey L Use of toxoplasma and derived compositions to prevent or treat microbial infections
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
GB0921525D0 (en) * 2009-12-08 2010-01-27 Isis Innovation Product and method
FR2962335B1 (fr) * 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
US9468662B2 (en) 2010-07-12 2016-10-18 Orphit Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases
WO2012138377A2 (en) 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
BR122021002471B8 (pt) 2011-03-03 2022-10-25 Impel Neuropharma Inc Dispositivo de distribuição de droga nasal
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
WO2012154859A1 (en) 2011-05-09 2012-11-15 Impel Neuropharma Inc. Nozzles for nasal drug delivery
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
PL3415139T3 (pl) 2011-06-14 2022-07-11 Neurelis, Inc. Podawanie benzodiazepiny
WO2012174481A1 (en) 2011-06-15 2012-12-20 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
WO2013134777A1 (en) 2012-03-09 2013-09-12 Northeastern University Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
US9033912B2 (en) 2012-03-28 2015-05-19 Warsaw Orthopedic, Inc. Drug delivery system
US20130280297A1 (en) 2012-04-11 2013-10-24 Lori Neal Use of toxoplasma gene products to prevent or treat microbial infections
US10279012B2 (en) 2013-03-11 2019-05-07 Healthpartners Research & Education Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
JP2016520378A (ja) 2013-04-28 2016-07-14 インペル ニューロファーマ インコーポレイテッド 医用単位用量コンテナ
KR20160010526A (ko) 2013-05-15 2016-01-27 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달
US9901684B2 (en) 2013-10-17 2018-02-27 Warsaw Orthopedic, Inc. Drug delivery device with retaining member
US10314911B2 (en) 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
US20170119851A1 (en) 2014-05-19 2017-05-04 Novartis Ag Methods of treating anorexia
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
USD809652S1 (en) 2014-07-25 2018-02-06 Warsaw Orthopedic, Inc. Drug delivery device
US10080877B2 (en) 2014-07-25 2018-09-25 Warsaw Orthopedic, Inc. Drug delivery device and methods having a drug cartridge
JP7030517B2 (ja) 2015-01-07 2022-03-07 トライジェミナ， インコーポレイテッド マグネシウム含有オキシトシン製剤および使用の方法
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
US10335435B2 (en) 2015-05-22 2019-07-02 Marco Merida Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
KR20190008237A (ko) 2016-04-15 2019-01-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ii형 점액다당류증의 치료를 위한 유전자 요법
USD802757S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
CN106620656A (zh) * 2017-03-03 2017-05-10 上海唯科生物制药有限公司 一种肿瘤坏死因子舌下给药制剂及其制备方法
NZ762881A (en) 2017-09-19 2024-03-22 Advaxis Inc Compositions and methods for lyophilization of bacteria or listeria strains
JP7449223B2 (ja) 2017-09-22 2024-03-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ムコ多糖症ｉｉ型を治療するための遺伝子療法
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
WO2019241579A1 (en) 2018-06-13 2019-12-19 Wisconsin Alumni Research Foundation Toxoplasma gondii vaccine
WO2020142206A1 (en) 2019-01-03 2020-07-09 Impel Neuropharma, Inc. Nasal drug delivery device
EP4319803A1 (en) 2021-04-08 2024-02-14 Vaxthera SAS Coronavirus vaccine comprising a mosaic protein
AU2022370099A1 (en) 2021-10-19 2024-05-30 Travis COCHRAN Breath-powered nasal devices for treatment of traumatic brain injury (tbi), including concussion, and methods and methods

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4462985A (en) * 1980-08-22 1984-07-31 University Of Illinois Foundation Delivery of biologically active components of heterologous species interferon isolates
US4479932A (en) * 1982-05-18 1984-10-30 University Of Florida Brain-specific drug delivery
US4820515A (en) * 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
US5910304A (en) * 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
US4497795A (en) * 1982-12-13 1985-02-05 The Texas A&M University System Method of regulating appetite and efficiency of food utilization employing interferon
SU1139444A1 (ru) 1982-12-15 1985-02-15 Iretskij Andrej N Способ введени нейротропных и гормональных препаратов
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4857316A (en) * 1984-10-03 1989-08-15 Syntex (U.S.A.) Inc. Synergistic antiviral composition
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4820514A (en) * 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
US5017371A (en) * 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
GB8918264D0 (en) * 1989-08-10 1989-09-20 Furnell David Rotary display unit
ATE156704T1 (de) 1989-12-05 1997-08-15 Ramsey Foundation Neurologische wirkstoffe zur nasalen verabreichung an das gehirn
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US5215741A (en) * 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
EP0566135A1 (en) * 1992-04-17 1993-10-20 Takeda Chemical Industries, Ltd. Transmucosal composition comprising a peptide and a cytidine derivative
DE69334237D1 (de) * 1992-06-22 2008-09-25 State Of Oregon Through Oregon Glycinrezeptorantagonisten und ihre verwendung
JPH0741428A (ja) 1993-07-30 1995-02-10 Teijin Ltd ペプチド、蛋白質性薬物経鼻・経肺製剤
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
US5675942A (en) * 1995-08-28 1997-10-14 Crawford; Van Wall panel alignment device and spacer
WO1997041884A1 (en) * 1996-05-09 1997-11-13 Pharma Pacific Pty. Ltd. Method of treatment
HUP9602024A3 (en) * 1996-07-25 1999-05-28 Toth Sandor Pharmaceutical composition containing aminoacid for external use
US6036949A (en) * 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
WO2000033814A2 (en) * 1998-12-09 2000-06-15 Chiron Corporation Method for administering agents to the central nervous system
ES2173679T3 (es) 1999-01-27 2002-10-16 Idea Ag Inmunizacion/transporte transnasal con vehiculos altamente adaptables.

Also Published As

Publication number Publication date
EP1237567A2 (en) 2002-09-11
US20020141971A1 (en) 2002-10-03
CA2393688A1 (en) 2001-06-14
WO2001041782A2 (en) 2001-06-14
DE60021760D1 (de) 2005-09-08
US20060159626A1 (en) 2006-07-20
DE60021760T2 (de) 2006-06-08
NO20022731D0 (no) 2002-06-07
US6991785B2 (en) 2006-01-31
NO20022731L (no) 2002-08-08
JP2003516360A (ja) 2003-05-13
AU783208B2 (en) 2005-10-06
WO2001041782A3 (en) 2002-01-17
ATE300952T1 (de) 2005-08-15
US20010043915A1 (en) 2001-11-22
EP1237567B1 (en) 2005-08-03
AU2069801A (en) 2001-06-18

Similar Documents

Publication Publication Date Title
IL150109A0 (en) Method for administering a cytokine to the central nervous system and the lymphatic system
WO2005000215A3 (en) Methods for treating pain
JP2003516360A5 (no)
Means et al. Progress in understanding the pathogenesis of the anemia of chronic disease [see comments]
CY1107995T1 (el) ΑΝΑΣΤΟΛΗ ΔΡΑΣΤΙΚΟΤΗΤΑΣ p38 ΚΙΝΑΣΗΣ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ΑΡΥΛ ΚΑΙ ΕΤEPΟΑΡΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΤEPΟΚΥΚΛΙΚΕΣ ΟΥΡΙΕΣ
WO2003002596A3 (en) Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders
HK1018595A1 (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis
NZ212632A (en) Tumor necrosis factor, its preparation and its use
ATE262920T1 (de) Kontinuierliche, niedrigdosierte zytokine- infusionstherapie
ATE435917T1 (de) Aav vektoren zur herstellung der medikamente zur konvektion-erhöhten verabreichung
AU2173400A (en) Method for administering agents to the central nervous system
WO2002038171A3 (en) METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE
DK1303495T3 (da) Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet
BR9814458A (pt) Composto, composição farmacêutica e método de tratamento de disfunções afetivas
EP1041982A4 (en) INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
IL161889A0 (en) Method for treating diseases with omega interferon
ATE65403T1 (de) Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
EP1127577A3 (en) Ligand for the c-kit receptor and methods of use thereof
US20100172869A1 (en) Method for treating multiple sclerosis
EP0231819A3 (en) Pharmaceutical agent for the treatment of myelogenous leukemia
TR199900527T2 (xx) N�rolojik bozukluklar�n tedavisi i�in benzopiranollerin kullan�m�.
AU1909995A (en) Co-administration of interleukin-3 mutant polypeptides with csf's for multi-lineage hematopoietic cell production
CA2255856A1 (en) Therapeutic uses for an aminosterol compound
AU2002241807A1 (en) Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
Wang et al. Treatment of leukemia with fibroblast-mediated interferon-alpha gene therapy alone or in combination with doxorubicin